Novo Nordisk ADR (NYSE:NVO) has a beta value of 0.43 and has seen 1.44 million shares traded in the recent trading session. The company, currently valued at $362.29B, closed the recent trade at $108.52 per share which meant it lost -$1.2 on the day or -1.09% during that session. The NVO stock price is -36.52% off its 52-week high price of $148.15 and 12.71% above the 52-week low of $94.73. If we look at the company’s 10-day average daily trading volume, we find that it stood at 6.09 million shares traded. The 3-month trading volume is 4.30 million shares.
The consensus among analysts is that Novo Nordisk ADR (NVO) is Buy stock at the moment, with a recommendation rating of 1.94. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Novo Nordisk ADR (NYSE:NVO) trade information
Sporting -1.09% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the NVO stock price touched $108.52 or saw a rise of 4.61%. Year-to-date, Novo Nordisk ADR shares have moved 4.90%, while the 5-day performance has seen it change -3.09%. Over the past 30 days, the shares of Novo Nordisk ADR (NYSE:NVO) have changed -7.85%. Short interest in the company has seen 6.36 million shares shorted with days to cover at 1.37.
Wall Street analysts have a consensus price target for the stock at $158, which means that the shares’ value could jump 31.32% from the levels at last check today.. The projected low price target is $156.0 while the price target rests at a high of $160.0. In that case, then, we find that the latest price level in today’s session is -47.44% off the targeted high while a plunge would see the stock gain -43.75% from the levels at last check today..
Novo Nordisk ADR (NVO) estimates and forecasts
Figures show that Novo Nordisk ADR shares have outperformed across the wider relevant industry. The company’s shares have lost -14.75% over the past 6 months, with this year growth rate of 11.11%, compared to 8.20% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 16.48% over the past 5 years. Earnings growth for 2024 is a modest 23.01% while over the next 5 years, the company’s earnings are expected to increase by 18.21%.
NVO Dividends
Novo Nordisk ADR is expected to release its next earnings report on 2024-Nov-06 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 1.45 at a share yield of 1.33%. The company’s dividend yield has gone up over the past 12 months, with a 5 Year Average Dividend Yield of 1.47%.
Novo Nordisk ADR (NYSE:NVO)’s Major holders
The top two institutional holders are JENNISON ASSOCIATES LLC with over 21.22 million shares worth more than $3.03 billion. As of 2024-06-30, JENNISON ASSOCIATES LLC held 0.4758% of shares outstanding.
The other major institutional holder is FMR LLC, with the holding of over 19.49 million shares as of 2024-06-30. The firm’s total holdings are worth over $2.78 billion and represent 0.4371% of shares outstanding.
